Cloudbreak Announces Final Endpoint Visit in Phase 3 Pterygium Trial for CBT-001

Cloudbreak Pharmaceuticals said on June 5, 2026, that the last patient has completed the final efficacy assessment in its Phase 3 study of CBT-001, an investigational eyedrop for pterygium. The milestone clears the way for the company to lock the trial database and report topline results in the coming weeks, moving the drug closer to a potential U.S. marketing application. CBT-001 targets the vascular and fibrotic processes that cause pterygium, a benign but progressive growth on the eye’s surface for which no FDA-approved pharmacotherapy exists. The randomized, multicenter trial enrolled patients scheduled for surgical removal; the primary endpoint measures lesion severity at a set time after dosing. A positive outcome would position Cloudbreak to file for approval in a market the company estimates at more than 200,000 surgical candidates annually in the United States alone. No serious safety signals have been reported to date.